المؤلفون: Dvornikov A.S., Gusev E.I., Martynov M.Y., Lashch N.Y., Gaydina T.A., Chukanova A.S., Boyko A.N.

المساهمون: 0

المصدر: Annals of the Russian academy of medical sciences; Vol 79, No 1 (2024); 15-22 ; Вестник Российской академии медицинских наук; Vol 79, No 1 (2024); 15-22 ; 2414-3545 ; 0869-6047 ; 10.15690/vramn.11

مصطلحات موضوعية: autoimmune diseases, autoimmune inflammation, multiple sclerosis, disease-modifying of multiple sclerosis, atopic dermatitis, psoriasis, vitiligo, alopecia, аутоиммунные заболевания, аутоиммунное воспаление, рассеянный склероз, препараты, изменяющие течение рассеянного склероза, атопический дерматит, псориаз, витилиго, алопеция

وصف الملف: application/pdf

Relation: https://vestnikramn.spr-journal.ru/jour/article/view/12461/1938; https://vestnikramn.spr-journal.ru/jour/article/view/12461/1912; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/12461/98513; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/12461/98511; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/12461/98512; https://vestnikramn.spr-journal.ru/jour/article/view/12461

الاتاحة: https://vestnikramn.spr-journal.ru/jour/article/view/12461
https://doi.org/10.15690/vramn12461

المؤلفون: S. A. Bedina, E. E. Mozgovaya, A. S. Trofimenko, S. S. Spicina, M. A. Mamus, С. А. Бедина, Е. Э. Мозговая, А. С. Трофименко, С. С. Спицина, М. А. Мамус

المصدر: Medical Immunology (Russia); Том 26, № 1 (2024); 175-180 ; Медицинская иммунология; Том 26, № 1 (2024); 175-180 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: реактивное воспаление, osteoarthritis, neutrophils, NETs, NETosis, autoimmune inflammation, reactive inflammation, остеоартрит, нейтрофилы, внеклеточные ловушки нейтрофилов, NETоз, аутоиммунное воспаление

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2672/1780; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/10823; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/10824; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/10825; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/10826; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/10827; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/10828; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/10829; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/10830; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/10831; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2672/12683; Бедина СА, Мозговая ЕЭ, Трофименко АС, Мамус МА, Спицина СС, Зборовская ИА. Внеклеточные ловушки нейтрофилов: динамика образования, ассоциированная с переходом от ремиссии к активному ревматоидному артриту // Сибирское медицинское обозрение. 2022. Т. 6. С. 86-92. doi:10.20333/2500-0136-2022-6-86-92; Бедина С.А., Мозговая Е.Э., Трофименко А.С., Спицина С.С., Мамус М.А. Образование внеклеточных ловушек нейтрофилами и моноцитами периферической крови больных ревматоидным артритом: изучение нового цитруллинсодержащего аутоантигена // Медицинская иммунология. 2021. Т. 23(5):1165-1170. doi:10.15789/1563-0625-FOE-2301.; Frangos T., Maret W. Zinc and Cadmium in the Aetiology and Pathogenesis of Osteoarthritis and Rheumatoid Arthritis. Nutrients. 2020, Vol. 13(1), pp. 53. doi:10.3390/nu13010053.; Gikaro J.M., Xiong H., Lin F. Activity limitation and participation restriction in Osteoarthritis and Rheumatoid arthritis: findings based on the National Health and Nutritional Examination Survey. BMC Musculoskelet Disord, 2022, Vol. 23(1), pp. 647. doi:10.1186/s12891-022-05607-z.; MacDonald I.J., Huang C.C., Liu S.C., Lin Y.Y., Tang C.H.Targeting CCN Proteins in Rheumatoid Arthritis and Osteoarthritis. Int J Mol Sci, 2021,Vol. 22(9), pp. 4340. doi:10.3390/ijms22094340.; Nieminen P., Hämäläinen W., Savinainen J., Lehtonen M., Lehtiniemi S., Rinta-Paavola J., Lehenkari P., Kääriäinen T., Joukainen A., Kröger H., Paakkonen T., Mustonen A.M. Metabolomics of Synovial Fluid and Infrapatellar Fat Pad in Patients with Osteoarthritis or Rheumatoid Arthritis. Inflammation, 2022, Vol. 45(3), pp. 1101-1117. doi:10.1007/s10753-021-01604-x.; Sun F., Zhou J.L., Peng P.J., Qiu C., Cao J.R., Peng H. Identification of Disease-Specific Hub Biomarkers and Immune Infiltration in Osteoarthritis and Rheumatoid Arthritis Synovial Tissues by Bioinformatics Analysis. Dis Markers, 2021, pp. 9911184. doi:10.1155/2021/9911184.; Wu S., Peng W., Liang X., Wang W. Anti-citrullinated protein antibodies are associated with neutrophil extracellular trap formation in rheumatoid arthritis. Journal of Clinical Laboratory Analysis, 2021, Vol. 35(3), pp. e23662. doi:10.1002/jcla.23662.; https://www.mimmun.ru/mimmun/article/view/2672

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2672
https://doi.org/10.15789/1563-0625-NET-2672

المؤلفون: D. B. Nizheharodava, A. Ch. Shuleika, A. M. Starastsin, M. I. Vanslau, G. I. Ivanchyk, A. V. Vialichka, M. M. Zafranskaya, Д. Б. Нижегородова, А. Ч. Шулейко, А. М. Старостин, М. И. Ванслав, Г. И. Иванчик, А. В. Величко, М. М. Зафранская

المصدر: Medical Immunology (Russia); Том 25, № 5 (2023); 1103-1110 ; Медицинская иммунология; Том 25, № 5 (2023); 1103-1110 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: мукозальный иммунитет, flow cytometry, Crohn's disease, colon, autoimmune inflammation, mucosal immunity, проточная цитометрия, болезнь Крона, толстая кишка, аутоиммунное воспаление

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2839/1771; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2839/11973; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2839/11974; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2839/11976; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2839/11978; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2839/11979; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2839/11980; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2839/11981; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2839/12308; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2839/12355; Casalegno G.R., Dabritz J. New insights on CD8+ T cells in inflammatory bowel disease and therapeutic approaches. Front. Immunol., 2021, Vol. 12, 738762. doi:10.3389/fimmu.2021.738762.; Catalan-Serra I., Sandvik A., Bruland T. Gamma delta T-Cells in Crohn's disease: a new player in the disease pathogenesis? J. Crohns Colitis, 2017, Vol. 11, no. 9, pp. 1135-1145.; Cheroutre H., Lambolez F., Mucida D. The light and dark sides of intestinal intraepithelial lymphocytes. Nat. Rev. Immunol., 2012, Vol. 11, no. 7, pp. 445-456.; Fergusson J.R., Fleming V.M., Klenerman P. CD161-expressing human T cells. Front. Immunol., 2011, Vol. 2, 36. doi:10.3389/fimmu.2011.00036.; Hu M.D., Edelblum K.L. Sentinels at the frontline: the role of intraepithelial lymphocytes in inflammatory bowel disease. Curr. Pharmacol. Rep., 2017, Vol. 3, no. 6, pp. 321-334.; Imam T., Park S., Kaplan M.H., Olson M.R. Effector T helper cell subsets in inflammatory bowel diseases. Front. Immunol., 2018, Vol. 1, no. 9, 1212. doi:10.3389/fimmu.2018.01212.; Kleinschek M.A., Boniface K., Sadekova S., Grein J., Murphy E.E., Turner S.P., Raskin L., Desai B., Faubion W.A., de Waal Malefyt R., Pierce R.H., McClanahan T., Kastelein R.A. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med., 2009, Vol. 206, no. 3, pp. 525-534.; Mayassi T., Jabri B. Human intraepithelial lymphocytes. Mucosal Immunol., 2018, Vol. 11, no. 5, pp. 1281-1289.; Mc Carthy N.E., Eberl M. Human '/O T-Cell control of mucosal immunity and inflammation. Front. Immunol., 2018, Vol. 9, 985. doi:10.3389/fimmu.2018.00985.; Nizheharodava D.B., Tsekhanovich D.A., Starostin A.M., Dybov O.G., Zafranskaya M.M. Subpopulations of circulating Y§-lymphocytes in patients with inflammatory bowel diseases. Journal of the Belarusian State University, Ecology. 2022, Vol. 4, pp. 79-88. (In Russ.); Nussler N.C., Stange B., Hoffman R.A., Schraut W.H., Bauer A.J., Neuhaus P Enhanced cytolytic activity of intestinal intraepithelial lymphocytes in patients with Crohn's disease. Langenbeck's Arch. Surg., 2000, Vol. 385, pp. 218-224.; Regner E.H., Ohri N., Stahly A., Gerich M.E., Fennimore B.P., Ir D., Jubair W.K., Gorg C., Siebert J., Robertson C.E., Caplan L., Frank D.N., Kuhn K.A. Functional intraepithelial lymphocyte changes in inflammatory bowel disease and spondyloarthritis have disease specific correlations with intestinal microbiota. Arthritis Res. Ther., 2018, Vol. 20, 149. doi:10.1186/s13075-018-1639-3.; van Dieren J.M., van der Woude C.J., Kuipers E.J., Escher J.C., Samsom J.N., Blumberg R.S., Nieuwenhuis E.S. Roles of CD1d-Restricted NKT cells in the intestine. Inflamm. Bowel Dis., 2007, Vol. 13, pp. 1146-1152.; van Kaer L., Olivares-Villagomez D. Intestinal intraepithelial lymphocytes development, homeostasis, and functions. J. Immunol. 2018, Vol. 200, pp. 2235-2244.; https://www.mimmun.ru/mimmun/article/view/2839

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2839
https://doi.org/10.15789/1563-0625-PCO-2839

المؤلفون: А. Yu. Sidorov, K. V. Fomina, L. V. Beduleva, А. Ю. Сидоров, К. В. Фомина, Л. В. Бедулева

المساهمون: This work was supported by the Ministry of Science and Higher Education of the Russian Federation (project number 0827-2020-0012)

المصدر: Medical Immunology (Russia); Том 25, № 3 (2023); 637-642 ; Медицинская иммунология; Том 25, № 3 (2023); 637-642 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: экспериментальная модель, HDL apoproteins, autoimmune inflammation, T lymphocytic infiltration, experimental mode, апопротеины ЛПВП, аутоиммунное воспаление, T-лимфоцитарная инфильтрация

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2699/1703; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/11870; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/11872; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/11874; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/11876; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/11877; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/11878; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/11879; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/11881; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/11882; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/12408; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/12416; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2699/12522; Burstein M., Scholnick H.R., Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid Res., 1970, Vol. 11, no. 6, pp. 583-595.; Cham B.E., Knowles B.R. A solvent system for delipidation of plasma or serum without protein precipitation. J. Lipid Res., 1976, Vol. 17, no. 2, pp. 176-181.; d’Elios M.M., Bergman M.P., Azzurri A., Amedei A., Benagiano M., de Pont J.J., Cianchi F., Vandenbroucke-Grauls C.M., Romagnani S., Appelmelk B.J., del Prete G. H(+),K(+)-atpase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology, 2001, Vol. 120, no. 2, pp. 377-386.; Fomina K., Beduleva L., Menshikov I., Anikaeva M., Suntsova D., Sidorov A., Stolyarova E. Immune response to native lipoproteins induces visceral obesity and aortic wall injury in rats: the role of testosterone. Endocr. Metab. Immune Disord. Drug Targets, 2017, Vol. 17, no. 2, pp. 125-133.; Fomina K., Beduleva L., Menshikov I., Zerjawi A., Terentiev A., Sidorov A., Khramova T., Abisheva N., Gorbushina A. Аtherosclerosislike changes in the rabbit aortic wall induced by immunization with native highdensity lipoproteins. Immun. Inflamm. Dis., 2020, Vol. 8, no. 4, pp. 559-567.; Kobiyama K., Ley K. Atherosclerosis. Circ. Res., 2018, Vol. 123, no. 10, pp. 1118-1120.; McLeod O., Silveira A., Fredrikson G.N., Gertow K., Baldassarre D., Veglia F., Sennblad B., Strawbridge R.J., Larsson M., Leander K., Gigante B., Kauhanen J., Rauramaa R., Smit A.J., Mannarino E., Giral P., Humphries S.E., Tremoli E., de Faire U., Ohrvik J., Nilsson J., Hamsten A. Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis. Atherosclerosis, 2014, Vol. 232, no. 1, pp. 242-248.; Meier L.A., Binstadt B.A. The contribution of autoantibodies to inflammatory cardiovascular pathology. Front. Immunol., 2018, Vol. 9, 911. doi:10.3389/fimmu.2018.00911.; Montecucco F., Vuilleumier N., Pagano S., Lenglet S., Bertolotto M., Braunersreuther V., Pelli G., Kovari E., Pane B., Spinella G., Pende A., Palombo D., Dallegri F., Mach F., Roux-Lombard P. Anti-Apolipoprotein A-1 autoantibodies are active mediators of atherosclerotic plaque vulnerability. Eur. Heart J., 2011, Vol. 32, pp. 412-421.; Ramos-Leví A.M., Marazuela M. Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms. Endocrinol. Nutr., 2016, Vol. 63, no. 8, pp. 421-429.; Stamler J., Daviglus M.L., Garside D.B., Dyer A.R., Greenland P., Neaton J.D. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA, 2000, Vol. 284, no. 3, pp. 311-318.; Verstappen G.M., Kroese F.G.M., Bootsma H. T cells in primary Sjögren’s syndrome: targets for early intervention. Rheumatology (Oxford), 2021, Vol. 60, no. 7, pp. 3088-3098.; Vuilleumier N., Montecucco F., Hartley O. Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World J. Cardiol., 2014, Vol. 6, no. 5, pp. 314-326.; Vuilleumier N., Reber G., James R., Burger D., de Moerloose P., Dayer J.M., Roux-Lombard P. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J. Autoimmun., 2004, Vol. 23, no. 4, pp. 353-360.; Yang Y., Charlton B., Shimada A., dal Canto R., Fathman C.G. Monoclonal T cells identified in early NOD islet infiltrates. Immunity, 1996, Vol. 4, no. 2, pp. 189-194.; https://www.mimmun.ru/mimmun/article/view/2699

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2699
https://doi.org/10.15789/1563-0625-HAI-2699

المؤلفون: E. B. Tatarnikova, O. I. Krivosheina, E. V. Ivanova, Е. Б. Татарникова, О. И. Кривошеина, Е. В. Иванова

المصدر: Medical Immunology (Russia); Том 24, № 1 (2022); 31-40 ; Медицинская иммунология; Том 24, № 1 (2022); 31-40 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: инфекция, pathogenesis, autoimmune inflammation, T cells, cytokines, infection, патогенез, аутоиммунное воспаление, Т-клетки, цитокины

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2395/1500; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2395/8783; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2395/8784; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2395/8785; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2395/8786; Баулина Н.М., Кулакова О.Г., Фаворова О.О. МикроРНК: роль в развитии аутоиммунного воспаления.// Acta Naturae (русскоязычная версия), 2016. Т. 8, № 1. C. 23-36.; Запускалов И.В., Кривошеина О.И., Хороших Ю.И. Патогенетические закономерности поражения центральных отделов глазного дна на фоне периферического увеита // Практическая медицина, 2012. № 4-2 (59). C. 100-104.; Хороших Ю.И., Иванова Е.В., Дениско М.С. Периферический увеит и миопия. // Современные технологии в офтальмологии, 2017. № 3. С. 156-157.; Agarwal M., Majumder P.D., Babu K., Konana V.K., Goyal M., Touhami S., Stanescu-Segall D., Bodaghi B. Drug-induced uveitis: A review. Indian J. Ophthalmol., 2020, Vol. 68, no. 9, pp. 1799-1807.; Aggarwal R., Ringold S., Khanna D., Neogi T., Johnson S.R., Miller A., Brunner H.I., Ogawa R., Felson D., Ogdie A., Aletaha D., Feldman B.M. Distinctions between diagnostic and classification criteria? Arthritis Care Res. (Hoboken), 2015, Vol. 67, no. 7, pp. 891-897.; Agrawal R., Iyer J., Connolly J., Iwata D., Teoh S. Cytokines and biologics in non-infectious autoimmune uveitis: bench to bedside. Indian J. Ophthalmol., 2014, Vol. 62, no. 1, pp. 74-81.; Berker N., Sen E., Elgin U., Atilgan C.U., Dursun E., Yilmazbas P. Analysis of clinical features and visual outcomes of pars planitis. Int. Ophthalmol., 2018, Vol. 38, no. 2, pp. 727-736.; Blum-Hareuveni T., Seguin-Greenstein S., Kramer M,, Hareuveni G, Sharon Y., Friling R., Sharief L., Lightman S., Tomkins-Netzer O. Risk factors for the development of cataract in children with uveitis. Am. J. Ophthalmol., 2017, Vol. 177, pp. 139-143.; Cimino L., Aldigeri R., Marchi S., Mastrofilippo V., Viscogliosi F., Coassin M., Soldani A., Savoldi L., De Fanti A., Belloni L., Zerbini A., Parmeggiani M., Chersich M., Soriano A., Salvarani C., Fontana L. Changes in patterns of uveitis at a tertiary referral center in Northern Italy: analysis of 990 consecutive cases. Int. Ophthalmol., 2018, Vol. 38, no. 1, pp. 133-142.; Conway M.D., Stern E., Enfield D.B., Peyman G.A. Management of cataract in uveitis patients. Curr. Opin. Ophthalmol., 2018, Vol. 29, no. 1, pp. 69-74.; Cunningham E.T. Jr, Pavesio C.E., Goldstein D.A., Forooghian F., Zierhut M. Multiple Sclerosis-Associated Uveitis. Ocul. Immunol. Inflamm., 2017, Vol. 25, no. 3, pp. 299-301.; Cunningham E.T. Jr, Smith J.R., Tugal-Tutkun I., Rothova A., Zierhut M. Uveitis in children and adolescents. Ocul. Immunol. Inflamm., 2016, Vol. 24, no. 4, pp. 365-371.; Deitch I., Amer R., Tomkins-Netzer O., Habot-Wilner Z., Friling R., Neumann R., Kramer M. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefes Arch. Clin. Exp. Ophthalmol., 2018, Vol. 256, no. 4, pp. 801-808.; Dick A.D. Doyne lecture 2016: Intraocular health and the many faces of inflammation. Eye (Lond.), 2017, Vol. 31, no. 1, pp. 87-96.; Dick A.D., Tundia N., Sorg R., Zhao C., Chao J., Joshi A., Skup M. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology, 2016, Vol. 123, no. 3, pp. 655-662.; Engelhard S.B., Patel V., Reddy A.K. Intermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic USA. Clin. Ophthalmol. (Auckland, NZ), 2015, no. 9, pp. 1549-1555.; Forrester J.V., Kuffova L., Dick A.D. Autoimmunity, Autoinflammation, and Infection in Uveitis. Am. J. Ophthalmol., 2018, Vol. 189, pp. 77-85.; Forrester J.V., McMenamin P.G., Dando S.J. CNS infection and immune privilege. Nat. Rev. Neurosci., 2018, Vol. 19, no. 11, pp. 655-671.; Foster C.S., Kothari S., Anesi S.D., Vitale A.T., Chu D., Metzinger J.L., Cerón O. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv. Ophthalmol., 2016, Vol. 61, no. 1, pp. 1-17.; Friedman D.S., Holbrook J.T., Ansari H., Alexander J., Burke A, Reed S.B., Katz J., Thorne J.E., LightmanS.L., Kempen J.H.; MUST Research Group. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology, 2013, Vol. 120, no. 8, pp. 1571-1579.; Fu X., Chen Y., Chen D. The Role of Gut Microbiome in Autoimmune Uveitis. Ophthalmic Res., 2021, Vol. 64, no. 2, pp. 168-177.; Gery I., Caspi R.R. Tolerance Induction in Relation to the Eye. Front. Immunol., 2018, Vol. 9, 2304. doi:10.3389/fimmu.2018.02304.; Hamam R.N., Barikian A.W., Antonios R.S., Abdulaal M.R., Alameddine R.M., El Mollayess G., Mansour A.M. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocul. Immunol. Inflamm., 2016, Vol. 24, no. 3, pp. 319-326.; Heinz C., Schoonbrood S., Heiligenhaus A. Intermediate uveitis in children and young adults: differences in clinical course, associations and visual outcome. Br. J. Ophthalmol., 2014, Vol. 98, no. 8, pp. 1107-1111.; Horai R., Caspi R.R. Microbiome and Autoimmune Uveitis. Front. Immunol., 2019, Vol. 10, 232. doi:10.3389/fimmu.2019.00232.; Jabs D.A., Belfort R.Jr., Bodaghi B., Graham E., Holland G.N., Lightman S.L., Oden N., Palestine A.G., Smith J.R., Thorne J.E., Trusko B.E. Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Syphilitic Uveitis. Am. J. Ophthalmol., 2021,Vol. 228, pp. 182-191.; Jabs D.A., Denniston A.K., Dick А.D., Dunn J.P., Kramer M., Oden N., Okada A.A., Palestine A.G., Read R.W., Thorne J.E., Trusko B.E., Yeh S. The Standardization Of Uveitis Nomenclature Sun Working Group Classification criteria for pars planitis. Am. J. Ophthalmol., 2021. doi:10.1016/j.ajo.2021.03.045.; Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Perspectives standardization of uveitis nomenclature for reporting clinical data. Results of first international workshop. Am. J. Ophthalmol., 2005, Vol. 140, no. 3, pp. 509-516.; Jayakumar K., Agarwal A., Gupta V. Tubercular intermediate uveitis: The importance of meticulous multidisciplinary assessments. Indian J. Ophthalmol., 2019, Vol. 67, no. 11, pp. 1873-1874.; Kaur C., Foulds W.S., Ling E.A. Blood–retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog. Retin. Eye Res., 2008, Vol. 27, no. 6, pp. 622-647.; Kempen J.H., van Natta M.L., Altaweel M.M., Dunn J.P., Jabs D.A., Lightman S.L., Thorne J.E., Holbrook J.T. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Factors predicting visual acuity outcome in intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment (MUST) trial. Am. J. Ophthalmol., 2015, Vol. 160, no. 6, pp. 1133-1141.; Kerr E.C., Copland D.A., Dick A.D., Nicholson L.B. The dynamics of leukocyte infiltration in experimental autoimmune uveoretinitis. Prog. Retin. Eye Res., 2008, Vol. 27, no. 5, pp. 527-535.; Kosmaczewska A., Przeździecka-Dołyk J., Turno-Kręcicka A., Ciszak L., Szteblich A., Węgrzyn A., Frydecka I., Misiuk-Hojło M. Imbalance in PB IL-17-Secreting and Regulatory Cells in Pars Planitis Is Associated with Dysregulation of IFN-γ-Secreting Cells, Especially in Patients with Clinical Complications. Mediators Inflamm., 2020, Vol. 2020, 9175083. doi:10.1155/2020/9175083.; Leclercq M., Desbois A.C., Domont F., Maalouf G., Touhami S., Cacoub P., Bodaghi B., Saadoun D. Biotherapies in Uveitis. J. Clin. Med., 2020, Vol. 9, no. 11, 3599. doi:10.3390/jcm9113599.; Lee R.W., Nicholson L.B., Sen H.N., Chan C.C., Wei L., Nussenblatt R.B., Dick A.D. Autoimmune and autoinflammatory mechanisms in uveitis. Semin. Immunopathol., 2014, Vol. 36, no. 5, pp. 581-594.; Levinson R.D. Immunogenetics of ocular inflammatory disease. Tissue Antigens, 2007, Vol. 69, no. 2, pp. 105-112.; Levy-Clarke G., Jabs D.A., Read R.W., Rosenbaum J.T., Vitale A., van Gelder R.N. Expert panel recommendations for the use of anti–tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology, 2014, Vol. 121, no. 3, pp. 785-796.; Liberman P., Gauro F., Berger O., Urzua C.A. Causes of uveitis in a tertiary center in Chile: a cross-sectional retrospective review. Ocul. Immunol. Inflamm., 2015, Vol. 23, no. 4, pp. 339-345.; Lin P., Suhler E.B., Rosenbaum J.T. The future of uveitis treatment. Am. Acad. Ophthalmol., 2014, Vol. 121, no. 1, pp. 365-376.; Lindner E., Steinwender G., Plainer S., Poeschl E.M., Weger M., Ardjomand N., Renner W., El-ShabrawiY. Role of IL-10 gene polymorphisms in intermediate and HLA-B27-associated uveitis. Acta Ophthalmol., 2013, Vol. 91, no. 5, pp. e415-e417.; Llop S.M., Papaliodis G.N. Cataract Surgery Complications in Uveitis Patients: A Review Article. Semin. Ophthalmol., 2018, Vol. 33, no. 1, pp. 64-69.; Llorenç V., Mesquida M., Sainz de la Maza M., Keller J., Molins B., Espinosa G., Hernandez M.V., Gonzalez-Martín J., Adán A. Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization. Acta Ophthalmol., 2015, Vol. 93, no. 6, pp. 561-567.; Luca C., Raffaella A., Sylvia M., Valentina M., Fabiana V., Marco C., Annamaria S., Luisa S., Alessandro F., Lucia B., Alessandro Z., Maria P., Matthew C., Alessandra S., Carlo S., Luigi F. Complications in Intermediate Uveitis: Prevalence, Time of Onset, and Effects on Vision in Short-Term and Long-Term Follow-Up. Ocul. Immunol. Inflamm., 2018, Vol. 38, no. 1, pp. 133-142.; Miserocchi E., Fogliato G., Modorati G., Bandello F. Review on the worldwide epidemiology of uveitis. Eur. J. Ophthalmol., 2013, Vol. 23, no. 5, pp. 705-717.; Mölzer C., Heissigerova J., Wilson H.M., Kuffova L., Forrester J.V. Immune Privilege: The Microbiome and Uveitis. Front. Immunol., 2021, Vol. 11, 608377. doi:10.3389/fimmu.2020.608377.; Ness T., Boehringer D., Heinzelmann S. Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center. Orphanet J. Rare Dis., 2017, Vol. 12, no. 1, 81. doi:10.1186/s13023-017-0638-9.; Nguyen Q.D., Merrill P.T., Jaffe G.J., Dick A.D., Kurup S.K., Sheppard J., Schlaen A., Pavesio C., Cimino L., van Calster J., Camez A.A., Kwatra N.V., Song A.P., Kron M., Tari S., Brézin A.P. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet, 2016, Vol. 388, no. 10050, pp. 1183-1192.; Ozdal P.C., Berker N., Tugal-Tutkun I. Pars planitis: Epidemiology, clinical characteristics, management and visual prognosis. J. Ophthalmic Vis. Res., 2015, Vol. 10, no. 4, pp. 469-480.; Ozzello D.J., Palestine A.G. Factors affecting therapeutic decisions in intermediate and posterior uveitis. Am. J. Ophthalmol., 2015, Vol. 159, no. 2, pp. 213-220.; Pålsson S., Andersson Grönlund M., Skiljic D., Zetterberg M. Phacoemulsification with primary implantation of an intraocular lens in patients with uveitis. Clin. Ophthalmol. (Auckland, NZ), 2017, Vol. 11, pp. 1549-1555.; Parchand S., Tandon M., Gupta V., Gupta A. Intermediate uveitis in Indian population. J. Ophthal. Inflamm. Infect., 2011, no. 1, pp. 65-70.; Perez V.L., Caspi R.R. Immune mechanisms in inflammatory and degenerative eye disease. Trends Immunol., 2015, Vol. 36, no. 6, pp. 354-363.; Perez V.L., Papaliodis G.N., Chu D., Anzaar F., Christen W., Foster C.S. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul. Immunol. Inflamm., 2004, Vol. 12, no. 3, pp. 193-202.; Placinta I.A., Udaondo P. Multimodal imaging in intermediate tuberculous uveitis. Arch. Soc. Esp. Oſtalmol. (Engl. Ed.), 2020, Vol. 95, no. 5, pp. e37-e38.; Przeździecka-Dołyk J., Węgrzyn A., Turno-Kręcicka A., Misiuk-Hojło M. Immunopathogenic background of pars planitis. Arch. Immunol. Ther. Exp., 2015, Vol. 64, no. 2, pp. 127-137.; Ratra D., Barh A., Banerjee M., Ratra V., Biswas J. Safety and Efficacy of Intravitreal Dexamethasone Implant for Refractory Uveitic Macular Edema in Adults and Children. Ocul. Immunol. Inflamm., 2018, Vol. 26, no. 7, pp. 1034-1040.; Raveney B.J., Copland D.A., Dick A.D., Nicholson L.B. TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis. J. Immunol., 2009, Vol. 183, no. 4, pp. 2321-2329.; Roemer S., Bissig A., Rocca A., Du Pasquier R., Guex-Crosier Y. Efficacy of natalizumab in intermediate uveitis related to multiple sclerosis: a case report. Klin. Monbl für Augenheilkd, 2018, Vol. 235, no. 4, pp. 476-477.; Rothova A., Hajjaj A., de Hoog J., Thiadens A.A.H.J., Dalm V.A.S.H. Uveitis causes according to immune status of patients. Acta Ophthalmol., 2019, Vol. 97, no. 1, pp. 53-59.; Schwartzman S., Schwartzman M. The use of biologic therapies in uveitis. Clin. Rev. Allergy Immunol., 2015, Vol. 49, no. 3, pp. 307-316.; Sen H.N., Abreu F.M., Louis T.A., Sugar E.A., Altaweel M.M., Elner S.G., Holbrook J.T., Jabs D.A., Kim R.Y., Kempen J.H. Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Cataract surgery outcomes in Uveitis: the multicenter Uveitis steroid treatment trial. Ophthalmology, 2016, Vol. 123, no. 1, pp. 183-190.; Shah A., Biswas J. Cytopathology and Polymerase Chain Reaction of Vitreous Fluid in Tubercular Intermediate Uveitis. Ocul. Immunol. Inflamm., 2020, pp. 1-3.; Shechter R., London A., Schwartz M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat. Rev. Immunol., 2013, Vol. 13, no. 3, pp. 206-218.; Shorstein N.H., Liu L., Waxman M.D., Herrinton L.J. Comparative effectiveness of three prophylactic strategies to prevent clinical macular edema aſter phacoemulsification surgery. Ophthalmology, 2015, Vol. 122, no. 12, pp. 2450-2456.; Shoughy S.S., Kozak I., Tabbara K.F. Associations of Systemic Diseases with Intermediate Uveitis. Ophthalmic Epidemiol., 2016, Vol. 23, no. 1, pp. 27-31.; Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Multiple Sclerosis-Associated Intermediate Uveitis. Am. J. Ophthalmol., 2021, Vol. 228, pp. 72-79.; Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Sarcoidosis-Associated Uveitis. Am. J. Ophthalmol., 2021, Vol. 228, pp. 220-230.; Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Intermediate Uveitis, Non-Pars Planitis Type. Am. J. Ophthalmol., 2021, Vol. 228, pp. 159-164.; Standardization of Uveitis Nomenclature (SUN) Working Group. Development of Classification Criteria for the Uveitides. Am. J. Ophthalmol., 2021, Vol. 228, pp. 96-105.; Stanford M.R., Vaughan R.W., Kondeatis E., Chen Y., Edelsten C.E., Graham E.M., Wallace G.R. Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom? Br. J. Ophthalmol., 2005, Vol. 89. no. 8, pp. 1013-1016.; Sugita S., Horie S., Yamada Y., Mochizuki M. Inhibition of B-cell activation by retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci., 2010, Vol. 51, Iss. 11, pp. 5783-5788.; Sugita S., Kawazoe Y., Imai A., Usui Y., Iwakura Y., Isoda K., Ito M., Mochizuki M. Mature dendritic cell suppression by IL-1 receptor antagonist on retinal pigment epithelium cells. Invest. Ophthalmol. Vis. Sci., 2013, Vol. 54, Iss. 5, pp. 3240-3249.; Sugita S. Role of ocular pigment epithelial cells in immune privilege. Arch. Immunol. Ther. Exp., 2009, Vol. 57, no. 4, pp. 263-268.; Sugita S., Horie S., Yamada Y., Kawazoe Y., Takase H., Mochizuki M. Suppression of interleukin-17-producing T-helper 17 cells by retinal pigment epithelial cells. Jpn J. Ophthalmol., 2011, Vol. 55, pp. 565-575.; Sugita S., Kawazoe Y., Imai A., Usui Y., Takahashi M., Mochizuki M. Suppression of IL-22-producing T helper 22 cells by RPE cells via PD-L1/PD-1 interactions. Invest. Ophthalmol. Vis. Sci., 2013, Vol. 54, Iss. 10, pp. 6926-6933.; Sun M.M., Levinson R.D., Filipowicz A., Anesi S., Kaplan H.J., Wang W., Goldstein D.A., Gangaputra S., Swan R.T., Sen H.N., Gordon L.K. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocul. Immunol. Inflamm., 2020, Vol. 28, no. 2, pp. 217-227.; Takai Y., Tanito M., Ohira A. Multiplex cytokine analysis of aqueous humor in eyes with primary open-angle glaucoma, exfoliation glaucoma, and cataract. Invest. Ophthalmol. Vis. Sci., 2012, Vol. 53, Iss. 1, pp. 241-247.; Tekin K., Erol Y.O., Sargon M.F., Inanc M., Ozdal P.C., Berker N. Effects of Fuchs uveitis syndrome on the ultrastructure of the anterior lens epithelium: A transmission electron microscopic study. Indian J. Ophthalmol., 2017, Vol. 65, no. 12, pp. 1459-1464.; Ten Berge J.C., Schreurs M.W.J., van Daele P.L.A., Rothova A. Autoimmunity in uveitis. Acta Ophthalmol., 2018, Vol. 96, no. 5, pp. 481-485.; Thorne J.E., Skup M., Tundia N., Macaulay D., Revol C., Chao J., Joshi A., Dick A.D. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmol., 2016, Vol. 94, no. 5, pp. e331-339.; Tode J., Richert E., Koinzer S., Klettner A., Pickhinke U., Garbers C., Rose-John S., Nölle B., Roider J. Intravitreal injection of anti-interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice. Cytokine, 2017, Vol. 96, pp. 8-15.; Tomkins-Netzer O., Lightman S., Drye L., Kempen J., Holland G.N., Rao N.A., Stawell R.J., Vitale A., Jabs D.A.; Outcome of treatment of uveitic macular edema: the multicenter uveitis steroid treatment trial 2-year results. Ophthalmology, 2015, Vol. 122, no. 11, pp. 2351-2359.; Tsirouki T., Dastiridou A., Symeonidis C., Tounakaki O., Brazitikou I., Kalogeropoulos C., Androudi S. A Focus on the Epidemiology of Uveitis. Ocul. Immunol. Inflamm., 2018, Vol. 26, no. 1, pp. 2-16.; Valentincic N.V., de Groot-Mijnes J.D., Kraut A., Korosec P., Hawlina M., Rothova A. Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol. Vis., 2011, Vol. 17, pp. 2003-2010.; Verhagen F.H., Bekker C.P.J., Rossato M., Hiddingh S., de Vries L., Devaprasad A., Pandit A., Ossewaardevan Norel J., Ten Dam N., Moret-Pot M.C.A., Imhof S.M., de Boer J.H., Radstake T.R.D.J., Kuiper J.J.W. A disease-associated microRNA cluster links inflammatory pathways and an altered composition of leukocyte subsets to noninfectious uveitis. Invest. Ophthalmol. Vis. Sci., 2018, Vol. 59, Iss. 2, pp. 878-888.; Vidović-Valentinčič N., Kraut A., Hawlina M., Stunf S., Rothova A. Intermediate uveitis: long-term course and visual outcome. Br. J. Ophthalmol, 2009, Vol. 93, no. 4, pp. 477-480.; Weinstein J.E., Pepple K.L. Cytokines in uveitis. Curr. Opin. Ophthalmol., 2018, Vol. 29, no. 3, pp.267-274.; Wen X., Hu X., Miao L., Ge X., Deng Y., Bible P.W., Wei L. Epigenetics, microbiota, and intraocular inflammation: New paradigms of immune regulation in the eye. Prog. Retin. Eye Res., 2018, Vol. 64, pp. 84-95.; Williams K.A., Esterman A.J., Bartlett C., Holland H., Hornsby N.B., Coster D.J. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation, 2006, Vol. 81, no. 6, pp. 896-901.; Winterhalter S., Behrens U.D., Salchow D., Joussen A.M., Pleyer U. Dexamethasone implants in paediatric patients with noninfectious intermediate or posterior uveitis: first prospective exploratory case series. BMC Ophthalmol., 2017, Vol. 17, no. 1, 252. doi:10.1186/s12886-017-0648-3.; Yoshimura T., Sonoda K.H., Ohguro N., Ohsugi Y., Ishibashi T., Cua D.J., Kobayashi T., Yoshida H., Yoshimura A. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford), 2009, Vol. 48, no. 4, pp. 347-354.; You C., Sahawneh H.F., Sahawneh M.L., Kubaisi B., Schmidt A., Foster C.S. A review and update on orphan drugs for the treatment of noninfectious uveitis. Clin. Ophthalmol., 2017, Vol. 11, pp. 257-265.; Yuen B.G., Tham V.M., Browne E.N., Weinrib R., Borkar D.S., Parker J.V., Uchida A., Vinoya A.C., Acharya N.R. Association between smoking and uveitis: results from the Pacific Ocular Inflammation Study. Ophthalmology, 2015, Vol. 122, no. 6, pp. 1257-1261.; Zola M., Briamonte C., Lorenzi U., Machetta F., Grignolo F.M., Fea A.M. Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone. Clin. Ophthalmol. (Auckland, NZ), 2017, Vol. 11, pp. 1949-1956.; https://www.mimmun.ru/mimmun/article/view/2395

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2395
https://doi.org/10.15789/1563-0625-MEA-2395

المؤلفون: V. G. Likhvantseva, E. V. Korosteleva, E. A. Rudenko, V. A. Vygodin, В. Г. Лихванцева, Екатерина Викторовна Коростелёва, Е. А. Руденко, В. А. Выгодин

المصدر: National Journal glaucoma; Том 13, № 1 (2014); 6-12 ; Национальный журнал Глаукома; Том 13, № 1 (2014); 6-12 ; 2311-6862 ; 2078-4104

مصطلحات موضوعية: аутоиммунное воспаление, endocrine ophthalmopathy, Grave’s disease, autoimmune inflammation, офтальмотонус, эндокринная офтальмопатия, болезнь Грейвса

وصف الملف: application/pdf

Relation: https://www.glaucomajournal.ru/jour/article/view/2/2; https://www.glaucomajournal.ru/jour/article/view/2/3; Данилов Г.Е. Влияние пунктурных воздействий на офтальмогипертензию, вызванную хроническим раздражением гипоталамуса и амигдалярного комплекса. Физиологический журнал им. И.М. Сеченова 1992; 78(12): 88-94.; Егоркина С.Б. Нервный и гормональный механизмы регуляции тонометрических, гидродинамических и биохимических показателей глаза при нейрогенном стрессе у экспериментальных животных. Дис. докт. мед. наук. Самара; 2011.; Волков В.В. Глаукома при псевдонормальном давлении. Москва: Медицина; 2001; 350 с; Нестеров А.П. Первичная открытоугольная глаукома: патогенез и принципы лечения. Клиническая офтальмология 2000; 1(1): 4-5; Flammer J., Mozaffarieh M. Pocket reference to ocular blood flow and glaucomatous optic neuropathy. Current Medicine Group 2008: 38-43.; Светлова О.В. Развитие теории оттока водянистой влаги и перспективные гипотензивные воздействия. Глаукома 2003; 1: 51-59.; Ticho U., Lahav M. Ocularchanges in rabbits with corticosteroid-induced ocular hypertension. Br J Ophtalmol 1980; 63(9): 646-650.; Шмырёва В.Ф., Петров С.Ю., Малинин Д.Е. Значение формы и степени деструкции дренажных путей для прогноза эффективности неперфорирующих антиглаукоматозных операций при первичной открытоугольной глаукоме. Глаукома. Журнал НИИ ГБ РАМН 2010; 3: 25-29.; Kok P., Barton К. Uveitic glaucoma. Ophthalmology Clinics of North America 2002; 15(3): 375-387.; Panek W.C., Holland G.N., Lee D.A., Chrisfensen R.E. Glaucoma patients with uveitis. Br J Ophthalmol 1990; 74(4): 223-227.; Smith K.D., Tevaarwerk G.J., Allen L.H. An ocular dynamic study supporting the hypothesis that hypothyroidism is a treatable cause of secondary open-angle glaucoma. Can J Ophthalmol 1992; 27(7): 341-344.; Новицкая Е.С. Ранняя диагностика постувеальной глаукомы и увеальной офтальмогипертензии у пациентов с хроническими увеитами. Клиническая офтальмология 2006; 4: 139-141.; Сасим И.В. Пятилетний опыт применения декомпрессионных операций в лечении пациентов с орбитопатией Грейвса. Здравоохранение Беларуси 2000; 9: 45-49; Lee H.B., Rodgers I.R., Woog J.J. Evaluation and management of Graves’ orbitopathy. Otolaryngol Clin N Am 2006; 39(5): 923-942.; Lyons D.E. Postural changes in IOP in dysthyroid exophthalmos. Trans Ophthalmol Soc UK 1971; 91: 799-803.; Бровкина А.Ф. Эндокринная офтальмопатия. Москва: Медицина; 2008; 176 с.; Аксенова М.С., Есауленко И.Э. Факторы риска как важный этап патогенеза первичной открытоугольной глаукомы. Естествознание и гуманизм 2007; 4(2): 25-29; Ekstrom C. Prevalence of open-angle glaucoma in central Sweden. The Tr. Glaucoma Survey. Acta Ophthalmol Scan 1996; 74(2): 107-112.; Егоров Е.А., Астахов Ю.С., Щуко А.Г. Национальное руководство (путеводитель) по глаукоме для поликлинических врачей. Москва, Столичный бизнес, 2008; 136 c.; Wiersinga W.M. Graves’ Orbitopathy. Basel: Karger; 2007; 1-26.; Алешаев М.И. Факторы риска развития первичной открытоугольной глаукомы. Учебное пособие для врачей. Пенза: ГОУ ДПО ПИУ; 2009; 14 c.; Алескерова П.М. Внутриглазная гидродинамика у пациентов с эндокринной офтальмопатией. Дис. . канд. мед. наук. Москва; 2010; Нестеров А.П., Бунин А.Я., Канцельсон Л.А. Внутриглазное давление. Москва: Наука; 1974; 391 c; Berhrouzi Z., Rabei H.M., Azizi F., Daftarian N., Mehrabi Y., Ardeshiri M., et al. Prevalence of open-angle glaucoma, glaucoma suspect, and ocular hypertension in thyroid-related immune orbitopathy. Glaucoma 2007; 16(4): 358-362.; Cockerham K.P., Pal C., Jani B., Wolter A., Kennerdell J.S. The prevalence and implications of ocular hypertension and glaucoma in thyroid-associated orbitopathy. Ophthalmology 1997; 104(6): 914-917.; Ohtsuka K., Sato A., Kawaguchi S. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves’ ophthalmopathy. Am J Ophthalmol 2003; 135(3): 285-290.; https://www.glaucomajournal.ru/jour/article/view/2

الاتاحة: https://www.glaucomajournal.ru/jour/article/view/2

المؤلفون: M. Volkov Yu., М. Волков Ю.

المصدر: Rheumatology Science and Practice; Vol 54, No 1 (2016); 78-85 ; Научно-практическая ревматология; Vol 54, No 1 (2016); 78-85 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20161

مصطلحات موضوعية: rheumatoid arthritis, innate immunity, pattern recognition receptors, Toll-like receptors, damage-associated molecular patterns, autoimmune inflammation, ревматоидный артрит, врожденный иммунитет, паттерн-распознающие рецепторы, Toll-подобные рецепторы, молекулярные паттерны, ассоциированные с повреждением, аутоиммунное воспаление

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2172/1393; Rock F. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci. 1998;95:588-93. doi:10.1073/pnas.95.2.588; Лебедев КА, Понякина ИД. Иммунология образраспознающих рецепторов: Интегральная иммунология. 2-е изд. Москва: Книжный дом «ЛИБРОКОМ»; 2013. 256 с. [Lebedev KA, Ponyakina ID. Immunologiya obrazraspoznayushchikh retseptorov: Integral’naya immunologiya [Immunology of image recognition receptors: Integrated Immunology]. 2nd ed. Moscow: Knizhnyi dom «LIBROKOM»; 2013. 256 p.].; Chen JQ, Szodoray P, Zeher M. Toll-like receptor pathways in autoimmune diseases. Clin Rev Allergy Immunol. 2015 Feb 17. [Epub ahead of print].; Cao Z, Henzel WJ, Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science. 1996;271:1128-31. doi:10.1126/science.271.5252.1128; Mansell A, Smith R, Doyle SL, et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol. 2006;7:148-55. doi:10.1038/ni1299; Goh FG, Midwood KS. Intrinsic danger: activation of Toll-like receptors inrheumatoid arthritis. Rheumatology (Oxford). 2012;51(1):7-23. doi:10.1093/rheumatology/ker257; Rogier R, Koenders MI, Abdollahi-Roodsaz S. Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis. J Immunol Res. 2015;2015:527696. doi:10.1155/2015/527696; Coenen MJH, Enevold C, Barrera P, et al. Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. PLoS One. 2010;5:e14326. doi:10.1371/journal.pone.0014326; Jaen O, Petit-Teixeira E, Kirsten H, et al. No evidence of major effects in several Toll-like receptor gene polymorphisms in rheumatoid arthritis. Arthritis Res Ther. 2009; 11:R5. doi:10.1186/ar2589; Etem EO, Elyas H, Ozgocmen S, et al. The investigation of tolllike receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients. Rheumatol Int. 2011;31:1369-74. doi:10.1007/s00296-010-1472-8; Enevold C, Radstake TRD, Coenen MJH, et al. Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritis. J Rheumatol. 2010;37:905-10. doi:10.3899/jrheum.090775; Davis ML, LeVan TD, Yu F, et al. Associations of toll-like receptor (TLR)-4 single nucleotide polymorphisms and rheumatoid arthritis disease progression: an observational cohort study. Int Immunopharmacol. 2015;24(2):346-52. doi:10.1016/j.intimp.2014.12.030; Sacre SM, Andreakos E, Kiriakidis S, et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol. 2007;170:518-25. doi:10.2353/ajpath.2007.060657; Brentano F, Schorr O, Gay RE, et al. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 2005;52:2656-65. doi:10.1002/art.21273; Sacre SM, Lo A, Gregory B, et al. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J Immunol. 2008;181:8002-9. doi:10.4049/jimmunol.181.11.8002; Ospelt C, Brentano F, Rengel Y, et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum. 2008;58:3684-92. doi:10.1002/art.24140; Roelofs MF, Wenink MH, Brentano F, et al. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann Rheum Dis. 2009;68:1486-93. doi:10.1136/ard.2007.086421; Tamaki Y, Takakubo Y, Hirayama T, et al. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol. 2011;38:810-20. doi:10.3899/jrheum.100732; Radstake TRDJ, Roelofs MF, Jenniskens YM, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum. 2004;50:3856-65. doi:10.1002/art.20678; Seibl R, Birchler T, Loeliger S, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol. 2003;162:1221-7. doi:10.1016/S0002-9440(10)63918-1; Pierer M, Rethage J, Seibl R, et al Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol. 2004;172:1256-65. doi:10.4049/jimmunol.172.2.1256; McGarry T, Veale DJ, Gao W, et al. Toll-like receptor 2 (TLR2) induces migration and invasive mechanisms in rheumatoid arthritis. Arthritis Res Ther. 2015 Jun 9;17:153. doi:10.1186/s13075-015-0664-8.; Chen Z, Su L, Xu Q, et al. IL-1R/TLR2 through MyD88 divergently modulates osteoclastogenesis through regulation of nuclear factor of activated T cells c1 (NFATc1) and B lymphocyte-induced maturation protein-1 (Blimp1). J Biol Chem. 2015 Oct 19. pii: jbc.M115.663518. [Epub ahead of print]. doi:10.1074/jbc.m115.663518; Hu F, Li Y, Zheng L, et al. Toll-like receptors expressed by synovial fibroblasts perpetuate Th1 and th17 cell responses in rheumatoid arthritis. PLoS One. 2014 Jun 17;9(6):e100266. doi:10.1371/journal.pone.0100266; Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 2005;52:2313-22. doi:10.1002/art.21278; Caiello I, Minnone G, Holzinger D, et al. IL-6 amplifies _LR mediated cytokine and chemokine production: implications for thepathogenesis of rheumatic inflammatory diseases. PLoS One. 2014;9(10):e107886.; Kim K-W, Cho M-L, Oh H-J, et al. ТLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Immunol Lett. 2009;124:9-17. doi:10.1016/j.imlet.2009.02.006; Kinnebrew MA, Buffie CG, Diehl GE, et al. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity. 2012 Feb 24;36(2):276-87. doi:10.1016/j.immuni.2011.12.011; Komai-Koma M, Li D, Wang E, et al. Anti-Toll-like receptor 2 and 4 antibodies suppress inflammatory response in mice. Immunology. 2014;143(3):354-62. doi:10.1111/imm.12312; Meng L, Zhu W, Jiang C, et al. Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats. Arthritis Res Ther. 2010;12(3):R103. doi:10.1186/ar3034; Zhu W, Meng L, Jiang C, et al. Overexpression of toll-like receptor 3 in spleen is associated with experimental arthritis in rats. Scand J Immunol. 2012 Sep;76(3):263-70. doi:10.1111/j.1365-3083.2012.02724.x; Yarilina A, DiCarlo E, Ivashkiv LB. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol. 2007;178(4):2204-11. doi:10.4049/jimmunol.178.4.2204; Hayashi T, Gray CS, Chan M, et al. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci U S A. 2009;106(8):2764-69. doi:10.1073/pnas.0813037106; Alzabin S, Kong P, Medghalchi M, et al. Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for ТLR7 in disease maintenance. Arthritis Res Ther. 2012;14(3):R142.; Chen SY, Shiau AL, Li YT, et al. Suppression of collagen-induced arthritis by intra-articular lentiviral vector-mediated delivery of Toll-like receptor 7 short hairpin RNA gene. Gene Ther. 2012;19(7):752-60. doi:10.1038/gt.2011.173; Demaria O, Pagni PP, Traub S, et al. ТLR8 deficiency leads to autoimmunity in mice. J Clin Invest. 2010;120(10):3651-62.; Miles K, Heaney J, Sibinska Z, et al. A tolerogenic role for Tolllike receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc Natl Acad Sci U S A. 2012;109(3):887-92. doi:10.1073/pnas.1109173109; Begovich AB, Carlton VE, Honigberg LA, et al. A missense singlenucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75(2):330-7. doi:10.1086/422827; Wang Y, Stanford S, Zhou W, et al. Rheumatoid arthritis-associated PTPN22 modulates toll-like receptor-mediated, type 1 interferon-dependent innate immunoregulation [abstract]. Arthritis Rheum. 2012;64(Suppl 10):2452.; Herman S, Fischer A, Pfatschbacher J, et al. A ТLR 9 antagonist diminishes arthritis severity in a rat model of rheumatoid arthritis. Ann Rheum Dis. 2011;70(Suppl 2):A39.; Isomä ki P, Alanä rä T, Isohanni P, et al. The expression of SOCS is altered in rheumatoid arthritis. Rheumatol Oxf Engl. 2007;46:1538-46. doi:10.1093/rheumatology/kem198; Tsao J-T, Kuo C-C, Lin S-C. The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients. Clin Exp Med. 2008;8:179-85. doi:10.1007/s10238-008-0006-0; Sanjuan MA, Rao N, Lai KT, et al. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol. 2006;172(7):1057-68. doi:10.1083/jcb.200508058; Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794-804. doi:10.4049/jimmunol.1000702; Thwaites R, Chamberlain G, Sacre S. Emerging role of endosomal Toll-like receptors in rheumatoid arthritis. Frontiers in Immunology. 2014;5:1. doi:10.3389/fimmu.2014.00001; Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191-5. doi:10.1038/nature00858; Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (Hmgb-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192:565-70. doi:10.1084/jem.192.4.565; Schierbeck H, Lundback P, Palmblad K, et al. Monoclonal antiHMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med. 2011;17:1039-44. doi:10.2119/molmed.2010.00264; Hamada T, Torikai M, Kuwazuru A, et al. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum. 2008;58:2675-85. doi:10.1002/art.23729; Foell D, Kane D, Bresnihan B, et al. Expression of the proinflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology. 2003;42:1383-9. doi:10.1093/rheumatology/keg385; Madland TM, Larsen A, Brun JG. S100 proteins calprotectin and S100A12 are related to radiographic changes rather than disease activity in psoriatic arthritis with low disease activity. J Rheumatol. 2007;34:2089-92.; Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516-21. doi:10.1038/nature01991; Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005;52:2936-46. doi:10.1002/art.21238; Campo GM, Avenoso A, D'Ascola A, et al. The inhibition of hyaluronan degradation reduced pro-inflammatory cytokines in mouse synovial fibroblasts subjected to collagen-induced arthritis. J Cell Biochem. 2012;113:1852-67. doi:10.1002/jcb.24054; Horton MR, Burdick MD, Strieter RM, et al. Regulation of hyaluronan-induced chemokine gene expression by IL-10 and IFN-γ in mouse macrophages. J Immunol. 1998;160:3023-30.; Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15:774-80. doi:10.1038/nm.1987; Goh FG, Piccinini AM, Krausgruber T, et al. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol. 2010;184:2655-62. doi:10.4049/jimmunol.0903359; Zhao X, Okeke N, Sharpe O, et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther. 2008;10:R94. doi:10.1186/ar2478; Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis Rheum. 2011;63:53-62. doi:10.1002/art.30081; Sanchez-Pernaute O, Filkova M, Gabucio A, et al. Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis. 2013;72:1400-6. doi:10.1136/annrheumdis-2012-201906; Cordova KN, Willis VC, Haskins K, Holers VM. A citrullinated fibrinogen-specific T cell line enhances autoimmune arthritis in a mouse model of rheumatoid arthritis. J Immunol. 2013;190:1457-65. doi:10.4049/jimmunol.1201517; Wendling U, Paul L, van der Zee R, et al. A conserved mycobacterial heat shock protein (hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue. J Immunol. 2000;164:2711-7. doi:10.4049/jimmunol.164.5.2711; Wieten L, Berlo SE, ten Brink CB, et al. IL-10 is critically involved in mycobacterial HSP70 induced suppression of proteoglycan-induced arthritis. PLoS One. 2009;4:e4186. doi:10.1371/journal.pone.0004186; O'Reilly S. Pound the alarm: danger signals in rheumatic diseases. Clin Sci (Lond). 2015;128(5):297-305. doi:10.1042/CS20140467; Mullen L, Chamberlain G, Sacre S. Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease. Arthritis Res Ther. 2015;17:122. doi:10.1186/s13075-015-0645-y; Idera Clinical Programs: Overview (2015) [цит. от 12.01.16]. Available from: http://www.iderapharma.com/; Musumeci D., Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharm Ther. 2013;141(3):347-57. doi:10.1016/j.pharmthera.2013.11.001; https://rsp.mediar-press.net/rsp/article/view/2172

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2172
https://doi.org/10.14412/1995-4484-2016-78-85

المؤلفون: T. Popkova V., D. Novikova S., E. Nasonov L., Т. Попкова В., Д. Новикова С., Е. Насонов Л.

المصدر: Rheumatology Science and Practice; Vol 54, No 2 (2016); 122-128 ; Научно-практическая ревматология; Vol 54, No 2 (2016); 122-128 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20162

مصطلحات موضوعية: rheumatoid arthritis, cardiovascular risk factors, autoimmune inflammation, disease-modifying antirheumatic drugs, biological agents, ревматоидный артрит, кардиоваскулярные факторы риска, аутоиммунное воспаление, базисные противовоспалительные препараты, генно-инженерные биологические препараты

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2200/1418; Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: национальное руководство. Москва: ГЭОТАР-Медиа; 2008. 720 с. [Nasonov EL, Nasonova VA, editors. Revmatologiya: natsional’noe rukovodstvo [Rheumatology: national guidelines]. Moscow: GEOTAR-Media; 2008. 720 p.].; Попкова ТВ, Новикова ДС, Насонов ЕЛ. Атеросклероз при ревматических заболеваниях. В кн.: Насонов ЕЛ, редактор. Ревматология: клинические рекомендации. Mосква: ГЭОТАР-Медиа; 2010. С. 678-702 [Popkova TV, Novikova DS, Nasonov EL. Atherosclerosis in rheumatic diseases. In: Nasonov EL, editor. Revmatologiya: klinicheskie rekomendatsii [Rheumatology: clinical guidelines]. Moscow: GEOTAR-Media; 2010. P. 678-702].; Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103:253-61. doi:10.1016/j.acvd.2010.03.007; Горбунова ЮН, Новикова ДС, Попкова ТВ и др. Кардиоваскулярный риск у больных ранним ревматоидным артритом до назначения базисной противовоспалительной терапии (предварительные данные исследования РЕМАРКА). Научно-практическая ревматология. 2014;52(4):381-6 [Gorbunova YuN, Novikova DS, Popkova TV, et al. Cardiovascular risk in patients with early rheumatoid arthritis before disease-modifying antirheumatic therapy (preliminary data of the REMARCА study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):381-6 (In Russ.)]. doi:10.14412/1995-4484-2014-381-386; Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722-32. doi:10.1002/art.20878; Новикова ДС, Попкова ТВ, Герасимов АН и др. Безболевая ишемия миокарда и нарушения ритма сердца у женщин с ревматоидным артритом. Клиницист. 2013;(3-4):31-40 [Novikova DS, Popkova TV, Gerasimov AN, et al. Silent myocardial ischemia and cardiac arrhythmias in women with rheumatoid arthritis. Klinitsist. 2013;(3-4):31-40 (In Russ.)].; Новикова ДС, Попкова ТВ, Мач ЭС, Насонов ЕЛ. Определение кальция в коронарных артериях: новые возможности стратификации риска развития сердечно-сосудистых осложнений у пациентов с аутоиммунными заболеваниями. Научно-практическая ревматология. 2009;47(3):60-6 [Novikova DS, Popkova TV, Mach ES, Nasonov EL. Calcium evaluation in coronary arteries: new possibilities of cardiovascular complications risk stratification in patients with autoimmune diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):60-6 (In Russ.)]. doi:10.14412/1995-4484-2009-1314; Kerola AM, Kauppi MJ, Kerola T, Nieminen TV. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis. 2012;71(10):1606-15. doi:10.1136/annrheumdis-2012-201334; Новикова ДС, Попкова ТВ, Герасимов АН и др. Взаимосвязь кардиоваскулярных факторов риска с ригидностью артериальной стенки у женщин с высокой активностью ревматоидного артрита. Рациональная фармакотерапия в кардиологии. 2012;8(6):756-65 [Novikova DS, Popkova TV, Gerasimov AN, et al. Interconnection of cardiovascular risk factors in arterial wall stiffness in women with a high activity of rheumatoid arthritis. Ratsional'naya Farmakoterapiya v Kardiologii. 2012;8(6):756-65 (In Russ.)].; Кириллова ИГ, Новикова ДС, Попкова ТВ и др. Диастолическая дисфункция левого и правого желудочков у больных ранним ревматоидным артритом до назначения базисной противовоспалительной терапии. Терапевтический архив. 2015;87(5):16-23 [Kirillova IG, Novikova DS, Popkova TV, et al. Diastolic dysfunction of the left and right ventricles in patients with early rheumatoid arthritis before the appointment of the basic anti-inflammatory therapy. Terapevticheskii Arkhiv. 2015;87(5):16- 23 (In Russ.)]. doi:10.17116/terarkh201587516-23; Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford). 2006;45 Suppl. 4:iv4- 7. doi:10.1093/rheumatology/kel313; Новикова ДС, Попкова ТВ, Герасимов АН и др. Взаимосвязь величины интервала QT и кардиоваскулярных факторов риска у женщин с ревматоидным артритом. Клиницист. 2013;(1):30-6 [Novikova DS, Popkova TV, Gerasimov AN, et al. The correlation between QT interval and cardiovascular risk factors in women with rheumatoid arthritis. Klinitsist. 2013;(1):30-6 (In Russ.)].; Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117952. doi:10.1371/journal.pone.0117952; Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482-7. doi:10.1136/ard.2010.135871; Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med. 2005;165(14):1624-9. doi:10.1001/archinte.165.14.1624; Zhang J, Chen L, Delzell E. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73(7):1301-8. doi:10.1136/annrheumdis-2013-204715; Garcia-Gomez C, Bianchi M, de la Fuente D, et al. Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship? World J Orthop. 2014;5(3):304-11. doi:10.5312/wjo.v5.i3.304; Ajeganova S, Andersson ML, Hafström I; BARFOT Study Group. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res (Hoboken). 2013;65(1):78-87. doi:10.1002/acr.21710; Кондратьева ЛВ, Горбунова ЮН, Попкова ТВ, Насонов ЕЛ. Роль жировой ткани при ревматоидном артрите. Клиническая медицина. 2014;(6):62-6 [Kondrat’eva LV, Gorbunova YuN, Popkova TV, Nasonov EL. The role of adipose tissue in rheumatoid arthritis. Klinicheskaya Meditsina. 2014;(6):62-6 (In Russ.)].; Новикова ДС, Попкова ТВ, Герасимов АН и др. Взаимосвязь показателей вариабельности ритма сердца с компонентами метаболического синдрома у женщин с ревматоидным артритом. Рациональная фармакотерапия в кардиологии. 2014;10(1):18-24 [Novikova DS, Popkova TV, Gerasimov AN, et al. Correlation of heart rate variability with components of the metabolic syndrome in women with rheumatoid arthritis. Ratsional’naya Farmakoterapiya v Kardiologii. 2014;10(1):18-24 (In Russ.)].; Кондратьева ЛВ, Попкова ТВ, Насонов ЕЛ. Метаболический синдром при ревматоидном артрите. Научно-практическая ревматология. 2013;51(3):302-12 [Kondratyeva LV, Popkova TV, Nasonov EL. Metabolic syndrome in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):302-12 (In Russ.)]. doi:10.14412/1995-4484-2013-1506; Hollan I, Dessein PH, Ronda N, et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev. 2015;14(10):952-69. doi:10.1016/j.autrev.2015.06.004; Barbarroja N, Perez-Sancherz C, Ouiz-Limon P, et al. Anticyclic citrullinsted protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014;34:2706-16. doi:10.1161/ATVBAHA.114.304475; Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010;69(11):1920-5. doi:10.1136/ard.2009.122226; Del Rincon I, Polak JF, O’Leary DH, et al. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1118-23. doi:10.1136/annrheumdis-2013-205058; Ambrosino P, Lupoli R, Di Minno A, et al. Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromb Haemost. 2015;113(5):916-30. doi:10.1160/TH14-11-0921; Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11:390-400. doi:10.1038/nrrheum.2015.40; Герасимова ЕВ, Попкова ТВ, Новикова ДС и др. 10-летний риск развития сердечно-сосудистых осложнений у больных ревматоидным артритом. Терапевтический архив. 2011;83(5):14-9 [Gerasimova EV, Popkova TV, Novikova DS, et al. 10-year risk of cardiovascular complications in patients with rheumatoid arthritis. Terapevticheskii Arkhiv. 2011;83(5):14-9 (In Russ.)].; Corrales A, Gonzalez-Juanatey C, Peiro ME, et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis. 2014;73(4):722-7. doi:10.1136/annrheumdis-2012- 203101; Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477-94 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):477-94 (In Russ.)]. doi:10.14412/1995-4484-2014-477-494; Humphreys JH, Warner A, Chipping J, et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: Results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken). 2014;66(9):1296-301. doi:10.1002/acr.22296; Kerola AM, Nieminen TV, Virta LJ, et al. No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000–2008. Clin Exp Rheumatol. 2015;33(3):391-8.; Meek IL, Vonkeman HE, van de Laar MAFJ. Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature. BMC Musculoskelet Disord. 2014;15:142. doi:10.1186/1471-2474-15-142; Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL. Cardiovascular effects of methotrexate in rheumatoid arthritis. Curr Med Chem. 2015;22:1903-10. doi:10.2174/0929867322666150415122039; Roubille C, Richer V, Startino T, et al. The effect of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Rheunm Dis. 2015;74:480-9. doi:10.1136/annrheumdis-2014-206624; Насонов ЕЛ. Метотрексат: перспективы применения в ревматологии. Москва: Филоматис; 2005. 200 с. [Nasonov EL. Metotreksat: perspektivy primeneniya v revmatologii [Methotrexate: prospects of application in rheumatology]. Moscow: Filomatis; 2005. 200 p.].; Bulgarelli A, Martins Dias AA, Caramelli B, Maranhao RC. Treatment with methotrexate inhibits atherogenesis in cholesterolfed rabbits. J. Cardiovasc Pharmacol. 2012;59:308-14. doi:10.1097/FJC.0b013e318241c385; Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-33 [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33 (In Russ.)]. doi:10.14412/1995-4484-2015- 421-433; Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7 Suppl 1:332-9. doi:10.1111/j.1538-7836.2009.03404.x; Erhayiem B, Pavitt S, Baxter P, et al. Coronary artery disease evaluation in rheumatoid arthritis (CADERA): study protocol for a randomized controlled trial. Trials. 2014;15:436. doi:10.1186/1745-6215-15-436; Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМАПРЕСС; 2013. 549 с. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 549 p.].; Попкова ТВ, Новикова ДС, Насонов ЕЛ. Интерлейкин-6 и сердечно-сосудистая патология при ревматоидном артрите. Научно-практическая ревматология. 2011;49(4):64-72 [Popkova TV, Novikova DS, Nasonov EL. Interleukin-6 and cardiovascular disease in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(4):64-72. (In Russ.)]. doi:10.14412/1995-4484-2011-63; Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-13. doi:10.1016/S0140- 6736(11)61931-4; Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379:1214-24. doi:10.1016/S0140- 6736(12)60110-X; Попкова ТВ, Новикова ДС, Панасюк ЕЮ и др. Влияние тоцилизумаба на систему транспорта холестерина крови и ранние проявления атеросклероза у больных ревматоидным артритом. Терапевтический архив. 2012;84(5):9-18 [Popkova TV, Novikova DS, Panasyuk EYu, et al. Effect of tocilizumab in the transport system of blood cholesterol and early signs of atherosclerosis in patients with rheumatoid arthritis. Terapevticheskii Arkhiv. 2012;84(5):9-18 (In Russ.)].; Удачкина ЕВ, Новикова ДС, Попкова ТВ и др. Динамика липидных параметров крови у больных ревматоидным артритом на фоне комбинированной терапии тоцилизумабом и метотрексатом в сравнении с монотерапией метотрексатом при 24-недельном наблюдении. Рациональная фармакотерапия в кардиологии. 2015;11(5):510-6 [Udachkina EV, Novikova DS, Popkova TV, et al. Dynamics of blood lipid parameters in patients with rheumatoid arthritis in the combined therapy tocilizumab and methotrexate compared to methotrexate monotherapy at 24 weeks of observation. Ratsional’naya Farmakoterapiya v Kardiologii. 2015;11(5):510-6 (In Russ.)].; Rao VU, Pavlov A, Klearman M, et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheum. 2015;67(2):372-80. doi:10.1002/art.38920; Novikova DS, Popkova TV, Nasonov EL. The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis. Cur Pharm Des. 2012;18:1512-8. doi:10.2174/138161212799504768; Novikova DS, Popkova TV, Lukina GV, et al. The effects of rituximab on lipids, arterial stiffness, and carotid intima-media thickness in rheumatoid arthritis. J Korean Med Sci. 2016;31:202-7. doi:10.3346/jkms.2016.31.2.202; Новикова ДС, Попкова ТВ, Герасимова ЕВ и др. Динамика частоты сердечных сокращений, показателей вариабельности ритма сердца и величины интервала Q–T у женщин с ревма- тоидным артритом на фоне лечения ритуксимабом. Научно-практическая ревматология. 2014;52(3):270-6 [Novikova DS, Popkova TV, Gerasimova EV, et al. Changes in heart rate, heart rate variability and QT interval in women with rheumatoid arthritis during rituximab treatment. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):270-6 (In Russ.)]. doi:10.14412/1995-4484-2014-270-276; Новикова ДС, Попкова ТВ, Насонов ЕЛ. Снижение кардиоваскулярного риска при ревматоидном артрите: двойная польза статинов. Научно-практическая ревматология. 2010;48(6):61-71 [Novikova DS, Popkova TV, Nasonov EL. Reduction of cardiovascular risk in rheumatoid arthritis: double benefit of statins. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(6):61-71 (In Russ.)]. doi:10.14412/1995-4484-2010-826; Новикова ДС, Попкова ТВ, Насонов ЕЛ. Статины как основа профилактики сердечно-сосудистых осложнений при ревматоидном артрите. Клиническая фармакология и терапия. 2011;20(1):65-73 [Novikova DS, Popkova TV, Nasonov EL. Statins as a basis for the prevention of cardiovascular complications in patients with rheumatoid arthritis. Klinicheskaya Farmakologiya i Terapiya. 2011;20(1):65-73 (In Russ.)].; Phan K, Gomez YH, Elbaz L, Daskalopoulou SS. Statin treatment non-adherence and discontinuation: clinical implications and potential solutions. Curr Pharm Des. 2014;20(40):6314-24. doi:10.2174/1381612820666140620162629; https://rsp.mediar-press.net/rsp/article/view/2200

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2200
https://doi.org/10.14412/1995-4484-2016-122-128

المؤلفون: ПОПКОВА ТАТЬЯНА ВАЛЕНТИНОВНА, НОВИКОВА Д.С., НАСОНОВ Е.Л.

مصطلحات موضوعية: РЕВМАТОИДНЫЙ АРТРИТ,КАРДИОВАСКУЛЯРНЫЕ ФАКТОРЫ РИСКА,АУТОИММУННОЕ ВОСПАЛЕНИЕ,БАЗИСНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ ПРЕПАРАТЫ,ГЕННО-ИНЖЕНЕРНЫЕ БИОЛОГИЧЕСКИЕ ПРЕПАРАТЫ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/serdechno-sosudistye-zabolevaniya-pri-revmatoidnom-artrite-novye-dannye
http://cyberleninka.ru/article_covers/17022513.png

المؤلفون: ВОЛКОВ М.Ю.

مصطلحات موضوعية: РЕВМАТОИДНЫЙ АРТРИТ,ВРОЖДЕННЫЙ ИММУНИТЕТ,ПАТТЕРН-РАСПОЗНАЮЩИЕ РЕЦЕПТОРЫ,TOLL-ПОДОБНЫЕ РЕЦЕПТОРЫ,АУТОИММУННОЕ ВОСПАЛЕНИЕ,RHEUMATOID ARTHRITIS,INNATE IMMUNITY,PATTERN RECOGNITION RECEPTORS,TOLL-LIKE RECEPTORS,DAMAGE-ASSOCIATED MOLECULAR PATTERNS,AUTOIMMUNE INFLAMMATION,МОЛЕКУЛЯРНЫЕ ПАТТЕРНЫ,АССОЦИИРОВАННЫЕ С ПОВРЕЖДЕНИЕМ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/rol-toll-podobnyh-retseptorov-i-ih-endogennyh-ligandov-v-patogeneze-revmatoidnogo-artrita-obzor-literatury
http://cyberleninka.ru/article_covers/17022506.png

المؤلفون: Григорьев, С. С., Ронь, Г. И., Ларионов, Л. П., Хонина, Т. Г.

المصدر: Сборник статей

مصطلحات موضوعية: S’OGRENE SYNDROME, SALIVARY GLANDS, AUTOIMMUNE INFLAMMATION, СИНДРОМ ШЕГРЕНА, СЛЮННЫЕ ЖЕЛЕЗЫ, АУТОИММУННОЕ ВОСПАЛЕНИЕ

وصف الملف: application/pdf

Relation: I Всероссийское рабочее совещание по проблемам фундаментальной стоматологии 23 января 2013 года : сборник статей Всероссийского конгресса «Стоматология Большого Урала» 12-14 декабря 2012 года; Применение новых композиций лекарственных препаратов на основе кремнийорганического глицерогидрогеля в комплексной стоматологической реабилитации больных с синдромом Шегрена / С. С. Григорьев, Г. И. Ронь, Л. П. Ларионов, Т. Г. Хонина. - Текст: электронный // I Всероссийское рабочее совещание по проблемам фундаментальной стоматологии 23 января 2013 года : сборник статей Всероссийского конгресса «Стоматология Большого Урала» 12-14 декабря 2012 года.- Екатеринбург, ООО «Типография Для Вас», 2013. – С. 42-47.; http://elib.usma.ru/handle/usma/18571

الاتاحة: http://elib.usma.ru/handle/usma/18571

المؤلفون: Мясоедова, Е.

مصطلحات موضوعية: РЕВМАТОИДНЫЙ АРТРИТ, АУТОИММУННОЕ ВОСПАЛЕНИЕ, ФАКТОРЫ РИСКА, КАРДИОВАСКУЛЯРНЫЕ НАРУШЕНИЯ, ФАРМАКОТЕРАПИЯ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/rol-traditsionnyh-faktorov-riska-hronicheskogo-autoimmunnogo-vospaleniya-i-farmakoterapii-v-razvitii-kardiovaskulyarnyh-narusheniy
http://cyberleninka.ru/article_covers/14820796.png

المؤلفون: Григорьев, С., Ронь, Г., Ларионов, Л.

مصطلحات موضوعية: СИНДРОМ ШЕГРЕНА, СЛЮННЫЕ ЖЕЛЕЗЫ, АУТОИММУННОЕ ВОСПАЛЕНИЕ, A S'OGRENE SYNDROME

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/kompleksnyy-podhod-k-stomatologicheskoy-reabilitatsii-bolnyh-s-sindromom-shegrena-chast-1-razrabotka-novyh-kompozitsiy-lekarstvennyh
http://cyberleninka.ru/article_covers/10717145.png

المؤلفون: Новосельцев, С., Космиров, В.

مصطلحات موضوعية: ГРЫЖА МЕЖПОЗВОНКОВОГО ДИСКА,ПРОВОСПАЛИТЕЛЬНЫЕ ЦИТОКИНЫ,ДИСКОГЕННАЯ РАДИКУЛОПАТИЯ,АУТОИММУННОЕ ВОСПАЛЕНИЕ,ДЕГЕНЕРАТИВНО-ДИСТРОФИЧЕСКИЕ ИЗМЕНЕНИЯ ПОЗВОНОЧНИКА,ПАТОБИОМЕХАНИКА ПОЗВОНОЧНИКА И КОСТЕЙ ТАЗА,ОСТЕОПАТИЯ,ГРИЖА МіЖХРЕБЦЕВОГО ДИСКА,ПРОЗАПАЛЬНі ЦИТОКіНИ,ДИСКОГЕННА РАДИКУЛОПАТіЯ,АУТОіМУННЕ ЗАПАЛЕННЯ,ДЕГЕНЕРАТИВНО-ДИСТРОФіЧНі ЗМіНИ ХРЕБТА,ПАТОБіОМЕХАНіКА ХРЕБТА і КіСТОК ТАЗУ,ОСТЕОПАТіЯ,HERNIA OF INTERVERTEBRAL DISK,PROINFLAMMATORY CYTOKINES,DISKOGENIC RADICULOPATHY,AUTOIMMUNE INFLAMMATION,DEGENERATIVE-DYSTROPHIC CHANGES IN SPINE,PATHOBIOMECHANICS OF SPINE AND PELVIS BONES,OSTEOPATHY

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/ob-uchastii-provospalitelnyh-tsitokinov-tnf-i-il-v-patogeneze-diskogennyh-bolevyh-sindromov
http://cyberleninka.ru/article_covers/15570168.png

المؤلفون: Andrievskih, I. A., Lukin, O. P., Nuzhdin, M. D., Dodonov, N. P., Андриевских, И. А., Лукин, О. П., Нуждин, М. Д., Додонов, Н. П.

مصطلحات موضوعية: AUTOIMMUNE INFLAMMATION, CORONARY REVASCULARIZATION, IMMUNOTHERAPY, АУТОИММУННОЕ ВОСПАЛЕНИЕ, КОРОНАРНАЯ РЕВАСКУЛЯРИЗАЦИЯ, ИММУНОКОРРЕКЦИЯ

وصف الملف: application/pdf

Relation: Уральский медицинский журнал. 2009. Т. 55, № 1.; Маркеры аутоиммунного воспаления в прикладной сердечно-сосудистой хирургии / И. А. Андриевских, О. П. Лукин, М. Д. Нуждин, Н. П. Додонов. – Текст: электронный // Уральский медицинский журнал. - 2009. – T. 55, № 1. – С. 35-39.; http://elib.usma.ru/handle/usma/16545

الاتاحة: http://elib.usma.ru/handle/usma/16545

المؤلفون: Anestiadi, V.V.

المصدر: Curierul Medical 303 (3) 153-155

مصطلحات موضوعية: vârstă, ateroscleroză, inflamaţie autoimună, fenomenul sinergistic, возраст, атеросклероз, аутоиммунное воспаление, феномен синергизма

وصف الملف: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/122879; urn:issn:18750666

الاتاحة: https://ibn.idsi.md/vizualizare_articol/122879

المؤلفون: T Popkova Y, D Novikova S, E. Gerasimova V., E Alexandrova N, A Novikov A, E Maeh S, S. Alekberova S., E Nasonov L, Д. Новикова С., А. Новиков А., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 46, No 4 (2008); 14-20 ; Научно-практическая ревматология; Vol 46, No 4 (2008); 14-20 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2008-4

مصطلحات موضوعية: autoimmune inflammation, systemic lupus erythematosus, metabolic syndrome, atherosclerosis, аутоиммунное воспаление, системная красная волчанка, метаболический синдром, атеросклероз

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/668/361; Насонова В. А. Системная красная волчанка. М., Медицина, 1972. Cervera R. Khamashta М. A., Font J. etal. Morbidity and mortality in systemic lupus erythematosus during a Ю-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore), 2003, 82, 299-308. Pistiner М., Wallance D. J., Nessim S. et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin. Arthr. Rheum., 1991, 21, 55-64. Bruce I. N., Urowitz М. B., Ibanez D., Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus. Arthr. Rheum., 2003, 48, 3159-67. Manzj S., Selzer F., Kuller L. H. et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthr. Rheum., 1999, 42, 51-60. Esdaile J. М., Abrahamowicz М., Grozicky T. et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthr. Rheum., 2001, 44. 223137. Насонов E. Л. Проблема атеротромбоза в ревматологии. Вестник РАМН, 2003, 7, 6-10. Chung С. P., Avalos /., OeserA. et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann. Rheum. Dis. 2007, 66, 208-214 Magadmi M, Ahmad Y., Turkie W. et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J. Rheumatol., 2006, 33, 50-56 Мамедов М. H., Перова H. В., Косматова О. В. и др. Перспективы коррекции проявлении метаболического синдрома, влияние сочетанной гипотензивной и гиполипидемической терапии на уровень суммарного коронарного риска и тканевую инсу- линорезистентность. Кардиология, 2003, 43, 3, 13-19 Wilson P. W, Kannel W. В., Silbershatz Н. et al. Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med., 1999, 159, 1104-1109 Насонов E. Л. Иммунологические маркеры атеросклероза. Тер. архив., 2002, 5, 80-85 Szmitko P. Е., Wang С. Н., Weisel R. D. et al. New markers of inflammation and endothelial cell activation, part I. Circulation, 2003, 108, 1917-1923 Szmitko P. E., Wang С. H., Weisel R. D. et al. New markers of inflammation and endothelial cell activation, pan II. Circulation, 2003, 108, 2041-2048 Насонов E. Л. Иммунологические маркеры атеросклероза. В кн. Антифосфолипидный синдром. М., Из-во «Литтера», 2004, 278-298 Visser М., Вой ter L. М., McQuillan G. М. et al. Elevated C-reactive protein levels in overweisht and obese adults. J. Am. Med. Assoc., 1999, 282, 21312135 Tsukui S., Kanda Т., Nara M. et al. Moderate- intensity regular exercise decreases tumor necrosis factor-a and HbAk levels in healthy women. Int. J. Obesity, 2000, 24, 1207-1211 Zahorska-Markiewicz B., Janowska J., Olszanecka- Glinianowicz M. Serum concentrations ofTNF-a and soluble TNF-a receptors in obesity. Int. J. Obesity. 2000, 24, 1392-1395 Frochlich М., Imhof A., Berg G. et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care, 2000, 23, 1835-1839 Festa A., DAgostino R. lr., Howard G. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2000, 102, 42-47 Blake G. J., Ridker P. M. Novel clinical markers of vascular wall inflammation. Circulation Res., 2001, 89, 763-771 Fernandez-Real J. М., Vayreda М., Richart C. et al. Circulating interleukin-6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J. Clin. Endocrinol. Metab., 2001, 86, 11541159 Tan E. N., Cohen A. S., Masi A. N. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr. Rheum., 1982,25, 1271-77. Vitali C., Bencivelli W, Isenberg D. A. et al. Disease activity in SLE: report of the Consensus Study Group of the European Workshop for Rheumatology Research. И Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin. Exp. Rheumatol., 1992,10. 541-47. Gladman D., Glizler E., Goldsmith C. et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthr. Rheum., 1996, 39, 363-369. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary’ of the second report of the national cholesterol education program (NCEP) expert panel detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA, 1993, 269, 3015-3023. National Cholesterol Education Program. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497 Диагностика и лечение стабильной стенокардии. Российские рекомендации. В НО К, М., 2004, 7-11 Howard G., Sharreit A. R., Heiss G. el at. Carotid artery intima-media thickness distribution in general populations as evaluated by В-mode ultrasound. ARIC Investigators. Stmke. 1993, 24. 1297-304 lannuzzi A., Michele M. D., Panico S. et al. Radical- Trapping Activity, Blood Pressure, and Carotid Enlargement in women. Hypertension., 2003, 41, 289-296 ArtissJ. D., Zak B. Measurement of cholesterol concentration. In: Rifai N. WarmicG. R., Dominiczak M. И., eds. Handbook of lipoprotein testing. Washington : AACC Press, 1997, 99-114 Friedwald W. Т., Levy R. J., Fredrickson D. S. Estimation of the calculation of LDL cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18, 499-502 Baikalt B., Charles M. A., Drivsholm T. etal. Freguence of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabet. Metab., 2002, 28, 364-367 Chung С. P., OeserA., Solus J. et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atliemsclerosis, 2007, 196, 765- 769 Karvounaris S. A., Sidiropoulos P. I., Papadakis J. A. et al. Metabolic syndrome is common among middle- to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann. Rheum. Dis., 2007, 66, 28-33 Roman M. J., Shanker B. A., Davis A. etal. Prevalence and correlates of accelerated atherosclerosis in Systemic lupus erythematosus. New Engl. J. Med., 2003, 349, 2399-2406. Rahman P., Urowitz М. B. Gladman D. D. et at. Contribution of traditional risk factor to coronary artery disease in patients with systemic lupus erythematosus. J. Rheumatol., 1999, 26, 363-368 Esdale J. М., Abrahamowicz М., Grodzicky T. et al. Traditional Framingham risk factor fail to fully account for accelerated atherosclemsis in systemic lupus erythematosus. Arthr. Rheum., 2001, 44, 23312337 Borba E. F., Bonfa E. Dyslipoproteinemias in SLE: influence of disease activity and anticardiolipin antibodies. Lupus, 1997, 6, 533-9. Kirwan J. P., Krishnan R. K., Weaver J. A. et al. Human aging is associated with altered TNF-a. production during hyperglycemia and hyperinsulinemia. Am. J. Physiol., 2001, 281, El 137-El 143 Lin Y., Rajala M. W, Berger J. P. etal. Hyperglycemia- induced production of acute phase reactants in adipose tissue. J. Biol. Chem., 2001, 276, 42077-42083 Chae C. U., Lee R. Т., Rifai N. et al. Blood pressure and inflammation in apparently healthy men. Hypertension, 2001, 38, 399-403 Панафидина Т. А., Попкова Т. В., Алекберова3. С. и соавт. Значение факторов риска и С-реактивного белка в развитии атеросклероза у женщин с системной красной волчанкой. Клин, мед., 2006, 10, 49-54 Tso Т. К., Huang W-N. Elevated soluble intercellular adhesion molecule-1 levels in patients with systemic lupus erythematosus: relation to insulin resistance. J. Rheumatol., 2007, 34, 726-730 Dessein P., Jojfe В. I., Stanwix A. E. et al. Clucocorticoids and insulin sensitivity in rheumatoid arthritis. J. Rheumatol., 2004, 31, 867-874 Boers М., Nurmohamed М. Т., Doelman CJA. et al. Influence glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2003, 62, 842-845; https://rsp.mediar-press.net/rsp/article/view/668

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/668
https://doi.org/10.14412/1995-4484-2008-530

المؤلفون: Попкова, Т., Новикова, Д., Герасимова, Е., Александрова, Е., Новиков, А., Мач, Э., Алекберова, З., Насонов, Е.

مصطلحات موضوعية: АУТОИММУННОЕ ВОСПАЛЕНИЕ, СИСТЕМНАЯ КРАСНАЯ ВОЛЧАНКА, МЕТАБОЛИЧЕСКИЙ СИНДРОМ, АТЕРОСКЛЕРОЗ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/metabolicheskiy-sindrom-u-bolnyh-sistemnoy-krasnoy-volchankoy
http://cyberleninka.ru/article_covers/14346077.png

المؤلفون: Черевко, Ольга Анатоліївна, Черевко, Ольга Анатольевна, Cherevko, O. A., Куч, Наталія Петрівна, Куч, Наталия Петровна, Kuch, N. P., Шкляренко, Вікторія Михайлівна, Шкляренко, Виктория Михайловна, Shklyarenko, V. M., Шапошник, Юрій Віталійович, Шапошник, Юрий Витальевич, Shaposhnyk, U. V.

مصطلحات موضوعية: атеросклероз, аутоімунне запалення, аутоиммунное воспаление, парадонтальна інфекція, парадонтальная инфекция, білки теплового шоку, белки теплового шока, ІХС, ИБС

Relation: Сучасний стан проблеми аутоімунних механізмів патогенезу ішемічної хвороби серця / О. А. Черевко, Н. П. Куч, В. М. Шкляренко, Ю. В. Шапошник // Актуальні проблеми сучасної медицини. – 2007.– Т. 7, Вип. 4 (20) – С. 360–364.; УДК 616.12-005.4-092; http://repository.pdmu.edu.ua/handle/123456789/2738

الاتاحة: http://repository.pdmu.edu.ua/handle/123456789/2738

المصدر: Научно-практическая ревматология.

مصطلحات موضوعية: РЕВМАТОИДНЫЙ АРТРИТ,КАРДИОВАСКУЛЯРНЫЕ ФАКТОРЫ РИСКА,АУТОИММУННОЕ ВОСПАЛЕНИЕ,БАЗИСНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ ПРЕПАРАТЫ,ГЕННО-ИНЖЕНЕРНЫЕ БИОЛОГИЧЕСКИЕ ПРЕПАРАТЫ

وصف الملف: text/html

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______2806::0ea0928aea48e27a25077527d54f9174
http://cyberleninka.ru/article_covers/17022513.png